Voxelotor对成人镰状细胞病患者脑灌注、脑氧代谢及心脏应激的影响
本研究在18例成人镰状细胞病(HbSS/HbSβ0-地中海贫血)患者中,于Voxelotor治疗(1500 mg/天)3个月前后的MRI测量脑血流动力学与氧代谢。血红蛋白显著升高(p=.001),溶血标志物下降(p<.05);氧输送增加,脑氧代谢率轻微下降,脑血流与脑血管储备未变;NT-proBNP下降(p=.048),TRVmax升高的患者中除一例外均恢复正常。
要点
- Voxelotor 1500 mg/天治疗3个月后血红蛋白显著升高(p=.001),溶血标志物下降(p<.05)。
- 氧输送从6.5增至8.1 mL O2/100 g/min(p=.001),脑血流与脑血管储备未变,脑氧代谢率轻微下降(p=.03)。
- NT-proBNP下降(p=.048),TRVmax升高的患者中除一例外均恢复正常。
核心结论
- Voxelotor治疗重度镰状细胞病患者虽升高血红蛋白,但未降低脑血流;脑氧代谢率轻微下降,可能源于药物诱导的氧结合增加;Voxelotor改善了临床验证的心脏应激标志物。
研究设计与样本
- 自身前后对照研究,18例成人镰状细胞病(HbSS/HbSβ0-地中海贫血)患者,Voxelotor 1500 mg/天治疗3个月,治疗前后用MRI测量脑血流动力学与氧代谢。
主要发现
- 血红蛋白水平显著升高(p=.001),溶血标志物下降(p<.05)。
- 氧输送从6.5(IQR,6.0-7.1)mL O2/100 g/min增至8.1(IQR,7.2-8.7)mL O2/100 g/min(p=.001)。
- 脑血流与脑血管储备未变。
- 脑氧代谢率从2.0(IQR,1.9-2.1)mL O2/100 g/min降至1.9(IQR,1.6-2.1)mL O2/100 g/min(p=.03)。
- NT-proBNP水平下降(p=.048),TRVmax升高的患者中除一例外均恢复正常。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sickle cell disease (SCD) is complicated by silent cerebral infarcts (SCIs), for which anemia is an important risk factor. Despite normal oxygen delivery (OD), cerebral vascular reserve (CVR), and cerebral metabolic rate of oxygen (CMRO2) are diminished in SCD, possibly causing the formation of SCIs. Voxelotor inhibits polymerization by increasing the hemoglobin oxygen binding, ameliorating hemolytic anemia. Furthermore, anemia is related to cardiac complications. Our aims were to assess the effect of voxelotor on markers of cerebral perfusion, cerebral oxygen metabolism, and markers of cardiac stress in SCD patients. Cerebral hemodynamics and oxygen metabolism were measured with MRI before and after 3 months of voxelotor treatment (1500 mg/day) in 18 adults with SCD (HbSS/HbSβ0-thalassemia). Hemoglobin levels significantly increased (p = .001) and markers of hemolysis decreased (p < .05). OD increased from 6.5 (IQR, 6.0-7.1) mL O2/100 g/min to 8.1 (IQR, 7.2-8.7) mL O2/100 g/min (p = .001). CBF and CVR did not change. CMRO2 decreased from 2.0 (IQR, 1.9-2.1) mL O2/100 g/min to 1.9 (IQR, 1.6-2.1) mL O2/100 g/min (p = .03). N-terminal pro-B type natriuretic peptide (NT-proBNP) levels decreased (p = .048) and maximum tricuspid regurgitation flow velocity (TRVmax) normalized in all but one patient with increased TRVmax. Voxelotor treatment in patients with severe SCD did not decrease CBF despite increased Hb levels. Cerebral oxygen metabolism slightly decreased, despite raised OD, most likely due to drug-induced increase in oxygen binding. Nonetheless, voxelotor improved clinically validated markers of cardiac stress.
引用
- Konté K, Afzali-Hashemi L, Baas KPA, et al. Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease. Am J Hematol. 2024. PMID: 39564863. doi:10.1002/ajh.27522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。